Tim Smith

In this study, investigators described the safety and tolerability of BLV therapy following 48 weeks of therapy among those with CHD.

This analysis involved assessing rates of lifetime as well as prior 12-month treatment use for AUD, in addition to demographic and clinical characteristics linked to AUD treatment.

Investigators looked at the effects of the exposome among patients with atopic dermatitis in order to better understand the influence of such elements as obesity and microorganisms.

These 52-week data highlight bimekizumab’s efficacy in the scalp, nail, and genital region for psoriasis, along with Dermatology Life Quality Index (DLQI) improvements.

In this month's episode of Lungcast, Jacob Sands, MD, discusses the American Lung Association’s recently newly-released 2024 State of Lung Cancer report.

This new edition of HCPLive’s monthly newsletter on recent US Food and Drug Administration (FDA) news features highlighted updates from across therapeutic pipelines.

In this analysis, investigators determined that the eliciting dose of an allergen may be an unpredictable marker for the severity of an allergic reaction.

These data highlight some of the most notable findings related to airline travel issues among those with food allergies or with family members with such allergies.

The phase 3 OLYMPIA 1 study highlights the benefits among those with prurigo nodularis of targeting interleukin-31 signaling using nemolizumab.

This pooled analysis of 3-year data yielded positive efficacy and safety findings for deucravacitinib treatment of those with psoriasis.

In this iteration of the Month in Review series, a list of highlighted stories in the allergy and immunology space covered in the month of November is provided.

The November Month in Review features a set of dermatology news coverage highlights, including FDA news and developments in psoriasis.

Two supplemental Biologics License Applications for guselkumab were submitted to the FDA for treatment of children with plaque psoriasis and active juvenile psoriatic arthritis.

These topline findings regarding MH004, or tofacitinib etocomil ointment 1.0%, demonstrated efficacy for this twice-daily pan-Jak inhibitor in adolescents and adults with eczema.

This portion of the latest Lungcast episode includes a discussion of therapies, triggers, and management of AERD.

During his interview, Criner discusses several notable updates to the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report regarding COPD care.

These findings indicate that incorporating educational video materials for psoriasis improved engagement in the shared decision-making process.

In this analysis, egg consumption among pregnant mothers was found to be insufficient for the development of oral tolerance to eggs among infants at 1 year of age.

The investigators of this study noted an association between obesity and conditions such as rosacea, psoriasis, and lichen simplex chronicus.

In this segment of the latest Lungcast episode, the characteristics of AERD and the concerns of patients were highlighted.

This study highlighted that both PASI scores and systemic inflammation, assessed using GlycA levels, were linked with cardiovascular disease.

In this analysis, the investigators systematically assessed links between the macronutrient profiles of common allergenic foods and corresponding prevalence of food allergy.

This meta-analysis showed that both secondary closure techniques substantially reduce the risk of hidradenitis suppurativa recurrence compared to primary direct closure.

The investigators concluded that chronic psychological stress substantially impacts skin homeostasis and, consequently, skin aging.

These retrospective, 52-week data highlight the efficacy and safety of bimekizumab for those with moderate-to-severe psoriasis.

This analysis evaluated the frequency of peanut-sensitized infants and toddlers being sensitized to other types of nuts.

UCB has announced the FDA’s approval of bimekizumab, also known as Bimzelx, for patients with moderate-to-severe HS.

In these guidelines compiled by the ACAAI, the AAAAI, and the AAOA, recommendations are provided to insurance companies for documentation needed for allergen immunotherapy.

These data were announced by Protagonist Therapeutics, resulting from the 2 pivotal ICONIC-LEAD and ICONIC-TOTAL studies on the oral peptide icotrokinra.

This segment of Han’s interview featured a discussion of the safety profile of dupilumab and ensifentrine, as well as other details in the GOLD 2025 Report.